$4.45
10.97% (Daily)
Market Cap
$230.87M
Revenue
$3.80M
Rank by MCap
#1071
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Joshua Mandel-Brehm
Headquarters
Cambridge, MA
Employees
55
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therape...
Loading chart…